Damora Therapeutics
DMRA
26 hedge funds and large institutions have $17.3M invested in Damora Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
13% more funds holding
Funds holding: 23 → 26 (+3)
10% more capital invested
Capital invested by funds: $15.7M → $17.3M (+$1.57M)
0.04% more ownership
Funds ownership: 36.04% → 36.08% (+0.04%)
20% less call options, than puts
Call options by funds: $56K | Put options by funds: $70K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$107K |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$85.2K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$40.6K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$36.7K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$20.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$137K |
| 2 |
Two Sigma Investments
New York
|
-$34K |
| 3 |
Two Sigma Advisers
New York
|
-$26.2K |
| 4 |
Millennium Management
New York
|
-$23.4K |
DMRA Hedge Fund Activity: Q3 2022 in Review
26 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q3 2022, worth a combined $17.3M — up 10% from $15.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new DMRA positions and 1 closed out — a net gain of 3 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $107K. The largest seller was Renaissance Technologies, cutting an estimated $137K.
- 26 institutional investors held Damora Therapeutics (DMRA) as of Q3 2022, up from 23 in Q2 2022.
- Funds reported $17.3M of Damora Therapeutics stock for Q3 2022, up 10% quarter-over-quarter.
- 4 funds opened new Damora Therapeutics positions in Q3 2022 and 1 closed out, a net change of +3 holders.
- The largest Damora Therapeutics buyer in Q3 2022 was Susquehanna International Group, an estimated $107K added.
- The largest Damora Therapeutics seller in Q3 2022 was Renaissance Technologies, an estimated $137K sold.
Based on aggregated 13F filings for Q3 2022.